Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer

British Journal of Cancer

Volumn 94, Issue 9, 2006, Pages 1267-1271

  Kinoshita, A ^a   Fukuda, M ^b,e   Soda, H ^c   Nagashima, S ^d   Takatani, H ^f   Kuba, M ^g   Nakamura, Y ^c   Tsurutani, J ^c   Kohno, S ^c   Oka, M ^b  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Sasebo General Hospital   (Japan)

^e Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^f Nagasaki Municipal Hospital   (Japan)

^g National Hospital Organization Okinawa National Hospital   (Japan)

Author keywords

Carboplatin; Chemotherapy; Clinical trial; Irinotecan; Small cell lung cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33646516226     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603079     Document Type: Article

References (37)

1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
2. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bogat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87: 573-580
3. De Marinis F, Migliorino MR, Paoluzzi L, Portalone L, Ariganello O, Cortesi E, Gamucci T, Gasperoni S, Cipri A, Martelli O, Nelli F (2003) Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer 39: 331-338
4. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33: 161-183
5. Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR (2004) Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol 22: 127-132
6. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing schema for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylato- platinum. Cancer Res 45: 6502-6506
7. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in a human small cell lung cancer cells. Cancer Res 56: 789-793
8. Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi K, Takatani H, Tsurutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A, Kohno S (1999) Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 5: 3936-3969
9. Fukuda M, Oka M, Soda H, Kinoshita A, Fukuda M, Nagashima S, Kuba M, Takatani H, Tsurutani J, Nakamura Y, Kasai T, Inoue Y, Soejima Y, Kohno S (2004) Phase II study of irinotecan combined with carboplatin in previously untreated non-small cell lung cancer. Cancer Chemother Pharmacol 54: 573-577
10. Georgoulias V, Mavroudis D, Veslemes M, Papakotoulas P, Syrigos K, Agelidou A, Pavlakou G, Rapti A, Polyzos A (2004) Comparison of the sequential versus the alternate administration of cisplatin-etoposide and topotecan regimens as first line treatment in extensive stage small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized trial. Proc Am Soc Clin Oncol 23: 624 (abstr 7045)
11. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422
12. Hanna N, Ansari R, Fisher W, Shen J, Jung SH, Sandler A (2002) Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiotherapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. Lung Cancer 35: 293-297
13. Hanna NH, Einhorn L, Sandler A, Langer C, Hariharan S, Ansari R, Ellis P, Byrne M, Wang B, Bunn P (2005) Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 23: 622s (abstr 7004)
14. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD (1989) Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720
15. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 3852-3859
16. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726
17. Kano Y, Akutsu M, Suzuki K, Yoshida M (1993) Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk Res 17: 113-119
18. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919-5924
19. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
20. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16: 1068-1074
21. Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 9: 13-21
22. Masuda N, Kudoh S, Fukuoka M (1996) Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol/Hematol 24: 3-26
23. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111: 1718-1723
24. Nagashima S, Fukuda M, Kinoshita A, Fukuda M, Kasai T, Takatani H, Rikimaru T, Soda H, Oka M, Kohno S (2004) Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) with concurrent split-course thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23: 655 (abstr 7169)
25. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23: 3752-3759
26. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91
27. Oka M, Fukuda M, Fukuda M, Kinoshita A, Kuba M, Ichiki M, Rikimaru T, Soda H, Takatani H, Narasaki F, Nagashima S, Nakamura Y, Hayashi N, Kohno S (2001) Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer. Eur J Cancer 37: 1359-1365
28. Oka M, Fukuda M, Kuba M, Ichiki M, Rikimaru T, Soda H, Tsurutani J, Nakamura Y, Kawabata S, Nakatomi K, Narasaki F, Nagashima S, Takatani H, Fukuda M, Kinoshita A, Kohno S (2002) Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur J Cancer 38: 1998-2004
29. Pujol JL, Carestia L, Daures JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? a meta-analysis of randomized trials of a cisplatin-containing regimen vs a regimen without this alkylating agent. Br J Cancer 83: 8-15
30. Rose WC, Schurig JE (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12: 1-19
31. Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr Jr GH, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR (2004) Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59: 943-951
32. Segawa Y, Ueoka H, Kiura K, Tabata M, Takigawa N, Hiraki Y, Watanabe Y, Yonei T, Moritaka T, Hiyama J, Hiraki S, Tanimoto M, Harada M (2003) Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer 41: 13-20
33. Simon GR, Wagner H (2003) Small cell lung cancer. Chest 123: 259S-271S
34. Simon R (1987) How large should be a phase II trial of a new drug? Cancer Treat Rep 71: 1079-1085
35. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20: 3054-3060
36. WHO (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO
37. Yokoyama A, Kurita Y, Saijo N, Tamura T, Noda K, Shimokata K, Matsuda T (1998) Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br J Cancer 78: 257-262